{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T18:26:34Z","timestamp":1778783194985,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31570772, 31771534"],"award-info":[{"award-number":["31570772, 31771534"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017528","name":"Key Discipline of Zhejiang Province in Medical Technology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100017528","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Key Research Project of Traditional Chinese Medicine of Zhejiang Province of China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ciclopirox (CPX) is an antifungal drug that has recently been reported to act as a potential anticancer drug. However, the effects and underlying molecular mechanisms of CPX on glioblastoma multiforme (GBM) remain unknown. Bortezomib (BTZ) is the first proteasome inhibitor-based anticancer drug approved to treat multiple myeloma and mantle cell lymphoma, as BTZ exhibits toxic effects on diverse tumor cells. Herein, we show that CPX displays strong anti-tumorigenic activity on GBM. Mechanistically, CPX inhibits GBM cellular migration and invasion by reducing N-Cadherin, MMP9 and Snail expression. Further analysis revealed that CPX suppresses the expression of several key subunits of mitochondrial enzyme complex, thus leading to the disruption of mitochondrial oxidative phosphorylation (OXPHOS) in GBM cells. In combination with BTZ, CPX promotes apoptosis in GBM cells through the induction of reactive oxygen species (ROS)-mediated c-Jun N-terminal kinase (JNK)\/p38 mitogen-activated protein kinase (MAPK) signaling. Moreover, CPX and BTZ synergistically activates nuclear factor kappa B (NF-\u03baB) signaling and induces cellular senescence. Our findings suggest that a combination of CPX and BTZ may serve as a novel therapeutic strategy to enhance the anticancer activity of CPX against GBM.<\/jats:p>","DOI":"10.1038\/s41419-021-03535-9","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T08:03:34Z","timestamp":1614931414000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK\/p38 MAPK and NF-\u03baB signaling"],"prefix":"10.1038","volume":"12","author":[{"given":"Zhipeng","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengnan","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiumei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningning","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junwan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fugen","family":"Shangguan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongzhang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianglong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengde","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohe","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiming","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9300-4542","authenticated-orcid":false,"given":"Bin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"issue":"Suppl 1","key":"3535_CR1","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1046\/j.1365-4362.42.s1.2.x","volume":"42","author":"AK Gupta","year":"2003","unstructured":"Gupta, A. K. & Skinner, A. R. Ciclopirox for the treatment of superficial fungal infections: a review. Int. J. Dermatol. 42(Suppl 1), S3\u2013S9 (2003).","journal-title":"Int. J. Dermatol."},{"issue":"4 Suppl","key":"3535_CR2","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1067\/mjd.2000.109072","volume":"43","author":"M Bohn","year":"2000","unstructured":"Bohn, M. & Kraemer, K. T. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J. Am. Acad. Dermatol. 43(4 Suppl), S57\u2013S69 (2000).","journal-title":"J. Am. Acad. Dermatol."},{"key":"3535_CR3","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1002\/ijc.25255","volume":"127","author":"H Zhou","year":"2010","unstructured":"Zhou, H. et al. The antitumor activity of the fungicide ciclopirox. Int J. Cancer 127, 2467\u20132477 (2010).","journal-title":"Int J. Cancer"},{"key":"3535_CR4","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.7150\/thno.34663","volume":"9","author":"J Zhou","year":"2019","unstructured":"Zhou, J. et al. CPX targeting DJ-1 triggers ros-induced cell death and protective autophagy in colorectal cancer. Theranostics 9, 5577\u20135594 (2019).","journal-title":"Theranostics"},{"key":"3535_CR5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/ijc.32709","volume":"146","author":"JA Braun","year":"2020","unstructured":"Braun, J. A. et al. Effects of the antifungal agent ciclopirox in HPV-positive cancer cells: Repression of viral E6\/E7 oncogene expression and induction of senescence and apoptosis. Int J. Cancer 146, 461\u2013474 (2020).","journal-title":"Int J. Cancer"},{"key":"3535_CR6","doi-asserted-by":"publisher","first-page":"10360","DOI":"10.18632\/oncotarget.23164","volume":"9","author":"C Mihailidou","year":"2018","unstructured":"Mihailidou, C., Papakotoulas, P., Papavassiliou, A. G. & Karamouzis, M. V. Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models. Oncotarget 9, 10360\u201310374 (2018).","journal-title":"Oncotarget"},{"key":"3535_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02779-1","volume":"11","author":"J Qi","year":"2020","unstructured":"Qi, J. et al. Ciclopirox activates PERK-dependent endoplasmic reticulum stress to drive cell death in colorectal cancer. Cell Death Dis. 11, 582 (2020).","journal-title":"Cell Death Dis."},{"key":"3535_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/ajh.23640","volume":"89","author":"MD Minden","year":"2014","unstructured":"Minden, M. D. et al. Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies. Am. J. Hematol. 89, 363\u2013368 (2014).","journal-title":"Am. J. Hematol."},{"key":"3535_CR9","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1158\/1078-0432.CCR-03-0781","volume":"10","author":"PF Bross","year":"2004","unstructured":"Bross, P. F. et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin. Cancer Res. 10, 3954\u20133964 (2004). 12 Pt 1.","journal-title":"Clin. Cancer Res."},{"key":"3535_CR10","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-03-0508","volume":"10","author":"J Cortes","year":"2004","unstructured":"Cortes, J. et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin. Cancer Res. 10, 3371\u20133376 (2004).","journal-title":"Clin. Cancer Res."},{"key":"3535_CR11","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1158\/1078-0432.CCR-06-2173","volume":"13","author":"TM Horton","year":"2007","unstructured":"Horton, T. M. et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children\u2019s Oncology Group study. Clin. Cancer Res. 13, 1516\u20131522 (2007).","journal-title":"Clin. Cancer Res."},{"key":"3535_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2012-04-418640","volume":"120","author":"YH Messinger","year":"2012","unstructured":"Messinger, Y. H. et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) study. Blood 120, 285\u2013290 (2012).","journal-title":"Blood"},{"key":"3535_CR13","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1158\/1078-0432.CCR-09-2882","volume":"16","author":"JJ Wright","year":"2010","unstructured":"Wright, J. J. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin. Cancer Res. 16, 4094\u20134104 (2010).","journal-title":"Clin. Cancer Res."},{"key":"3535_CR14","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/leu.2013.366","volume":"28","author":"D Koyama","year":"2014","unstructured":"Koyama, D. et al. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia. Leukemia 28, 1216\u20131226 (2014).","journal-title":"Leukemia"},{"key":"3535_CR15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00280-012-1953-4","volume":"70","author":"C Huang","year":"2012","unstructured":"Huang, C. et al. Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro. Cancer Chemother. Pharm. 70, 801\u2013809 (2012).","journal-title":"Cancer Chemother. Pharm."},{"key":"3535_CR16","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1158\/1078-0432.CCR-12-1511","volume":"19","author":"L Bastian","year":"2013","unstructured":"Bastian, L. et al. Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K\/AKT, and NF-\u03baB. Clin. Cancer Res. 19, 1445\u20131457 (2013).","journal-title":"Clin. Cancer Res."},{"key":"3535_CR17","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1007\/s00204-019-02579-3","volume":"93","author":"Y Li","year":"2019","unstructured":"Li, Y. et al. Artemisinin suppresses hepatocellular carcinoma cell growth, migration and invasion by targeting cellular bioenergetics and Hippo-YAP signaling. Arch. Toxicol. 93, 3367\u20133383 (2019).","journal-title":"Arch. Toxicol."},{"key":"3535_CR18","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s12035-018-1182-x","volume":"56","author":"A Comba","year":"2019","unstructured":"Comba, A., Bonnet, L. V., Goitea, V. E., Hallak, M. E. & Galiano, M. R. Arginylated calreticulin increases apoptotic response induced by bortezomib in glioma cells. Mol. Neurobiol. 56, 1653\u20131664 (2019).","journal-title":"Mol. Neurobiol."},{"key":"3535_CR19","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s10637-013-9968-1","volume":"31","author":"PJ Vlachostergios","year":"2013","unstructured":"Vlachostergios, P. J., Hatzidaki, E., Befani, C. D., Liakos, P. & Papandreou, C. N. Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner. Invest. N. Drugs 31, 1169\u20131181 (2013).","journal-title":"Invest. N. Drugs"},{"key":"3535_CR20","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.canlet.2018.06.012","volume":"432","author":"L Lan","year":"2018","unstructured":"Lan, L. et al. Deferoxamine suppresses esophageal squamous cell carcinoma cell growth via ERK1\/2 mediated mitochondrial dysfunction. Cancer Lett. 432, 132\u2013143 (2018).","journal-title":"Cancer Lett."},{"key":"3535_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-020-00612-7","volume":"18","author":"MY Chen","year":"2020","unstructured":"Chen, M. Y. et al. Preparation, characterization and in vitro-in vivo evaluation of bortezomib supermolecular aggregation nanovehicles. J. Nanobiotechnol. 18, 57 (2020).","journal-title":"J. Nanobiotechnol."},{"key":"3535_CR22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1158\/1535-7163.MCT-10-0725","volume":"10","author":"EP Jane","year":"2011","unstructured":"Jane, E. P., Premkumar, D. R. & Pollack, I. F. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway. Mol. Cancer Ther. 10, 198\u2013208 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"3535_CR23","doi-asserted-by":"publisher","first-page":"11609","DOI":"10.18632\/oncotarget.7018","volume":"7","author":"D Xie","year":"2016","unstructured":"Xie, D. et al. Downregulation of TFAM inhibits the tumorigenesis of non-small cell lung cancer by activating ROS-mediated JNK\/p38MAPK signaling and reducing cellular bioenergetics. Oncotarget 7, 11609\u201311624 (2016).","journal-title":"Oncotarget"},{"key":"3535_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2147\/JIR.S140188","volume":"11","author":"S Giridharan","year":"2018","unstructured":"Giridharan, S. & Srinivasan, M. Mechanisms of NF-\u03baB p65 and strategies for therapeutic manipulation. J. Inflamm. Res. 11, 407\u2013419 (2018).","journal-title":"J. Inflamm. Res."},{"key":"3535_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1158\/0008-5472.CAN-18-1733","volume":"79","author":"D Aasland","year":"2019","unstructured":"Aasland, D. et al. Temozolomide induces senescence and repression of DNA repair pathways in glioblastoma cells via activation of ATR-CHK1, p21, and NF-\u03baB. Cancer Res. 79, 99\u2013113 (2019).","journal-title":"Cancer Res."},{"key":"3535_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01366-x","volume":"8","author":"SK Sahu","year":"2017","unstructured":"Sahu, S. K. et al. FBXO32 promotes microenvironment underlying epithelial-mesenchymal transition via CtBP1 during tumour metastasis and brain development. Nat. Commun. 8, 1523 (2017).","journal-title":"Nat. Commun."},{"key":"3535_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10911-010-9177-x","volume":"15","author":"ES Radisky","year":"2010","unstructured":"Radisky, E. S. & Radisky, D. C. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J. Mammary Gland Biol. Neoplasia 15, 201\u2013212 (2010).","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"3535_CR28","doi-asserted-by":"publisher","first-page":"e0216385","DOI":"10.1371\/journal.pone.0216385","volume":"14","author":"D Detaille","year":"2019","unstructured":"Detaille, D., Pasdois, P., S\u00e9mont, A., Dos Santos, P. & Diolez, P. An old medicine as a new drug to prevent mitochondrial complex I from producing oxygen radicals. PloS One 14, e0216385\u2013e0216385 (2019).","journal-title":"PloS One"},{"key":"3535_CR29","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1242\/jeb.132142","volume":"220","author":"D Munro","year":"2017","unstructured":"Munro, D. & Treberg, J. R. A radical shift in perspective: mitochondria as regulators of reactive oxygen species. J. Exp. Biol. 220, 1170\u20131180 (2017).","journal-title":"J. Exp. Biol."},{"key":"3535_CR30","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1007\/s10637-012-9804-z","volume":"30","author":"A Zanotto-Filho","year":"2012","unstructured":"Zanotto-Filho, A., Braganhol, E., Battastini, A. M. O. & Moreira, J. C. F. Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K\/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1\/2 signaling. Invest N. Drugs 30, 2252\u20132262 (2012).","journal-title":"Invest N. Drugs"},{"key":"3535_CR31","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/sj.onc.1208225","volume":"24","author":"D Yin","year":"2005","unstructured":"Yin, D. et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 24, 344\u2013354 (2005).","journal-title":"Oncogene"},{"key":"3535_CR32","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.mce.2014.12.013","volume":"401","author":"J Vriend","year":"2015","unstructured":"Vriend, J. & Reiter, R. J. The Keap1-Nrf2-antioxidant response element pathway: a review of its regulation by melatonin and the proteasome. Mol. Cell Endocrinol. 401, 213\u2013220 (2015).","journal-title":"Mol. Cell Endocrinol."},{"key":"3535_CR33","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1007\/s12035-018-1152-3","volume":"56","author":"PM Wagner","year":"2019","unstructured":"Wagner, P. M. et al. Proliferative glioblastoma cancer cells exhibit persisting temporal control of metabolism and display differential temporal drug susceptibility in chemotherapy. Mol. Neurobiol. 56, 1276\u20131292 (2019).","journal-title":"Mol. Neurobiol."},{"key":"3535_CR34","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3892\/ijo.2016.3806","volume":"50","author":"X Bao","year":"2017","unstructured":"Bao, X. et al. Bortezomib induces apoptosis and suppresses cell growth and metastasis by inactivation of Stat3 signaling in chondrosarcoma. Int. J. Oncol. 50, 477\u2013486 (2017).","journal-title":"Int. J. Oncol."},{"key":"3535_CR35","doi-asserted-by":"publisher","first-page":"a000034","DOI":"10.1101\/cshperspect.a000034","volume":"1","author":"A Oeckinghaus","year":"2009","unstructured":"Oeckinghaus, A. & Ghosh, S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb. Perspect. Biol. 1, a000034\u2013a000034 (2009).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"3535_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nrd1279","volume":"3","author":"M Karin","year":"2004","unstructured":"Karin, M., Yamamoto, Y. & Wang, Q. M. The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev. Drug Discov. 3, 17\u201326 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3535_CR37","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.ejca.2006.01.011","volume":"42","author":"E Pikarsky","year":"2006","unstructured":"Pikarsky, E. & Ben-Neriah, Y. NF-kappaB inhibition: a double-edged sword in cancer? Eur. J. Cancer 42, 779\u2013784 (2006).","journal-title":"Eur. J. Cancer"},{"key":"3535_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrd2781","volume":"8","author":"V Baud","year":"2009","unstructured":"Baud, V. & Karin, M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. 8, 33\u201340 (2009).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3535_CR39","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/35009130","volume":"404","author":"KM Ryan","year":"2000","unstructured":"Ryan, K. M., Ernst, M. K., Rice, N. R. & Vousden, K. H. Role of NF-kappaB in p53-mediated programmed cell death. Nature 404, 892\u2013897 (2000).","journal-title":"Nature"},{"key":"3535_CR40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","volume":"5","author":"J-P Copp\u00e9","year":"2010","unstructured":"Copp\u00e9, J.-P., Desprez, P.-Y., Krtolica, A. & Campisi, J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99\u2013118 (2010).","journal-title":"Annu. Rev. Pathol."},{"key":"3535_CR41","doi-asserted-by":"publisher","first-page":"175909141989271","DOI":"10.1177\/1759091419892713","volume":"11","author":"PM Wagner","year":"2019","unstructured":"Wagner, P. M., Monjes, N. M. & Guido, M. E. Chemotherapeutic effect of SR9009, a REV-ERB agonist, on the human glioblastoma T98G cells. ASN Neuro 11, 1759091419892713 (2019).","journal-title":"ASN Neuro"},{"key":"3535_CR42","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1021\/acschemneuro.0c00095","volume":"11","author":"Z Yao","year":"2020","unstructured":"Yao, Z. et al. Ursodeoxycholic acid inhibits glioblastoma progression via endoplasmic reticulum stress related apoptosis and synergizes with the proteasome inhibitor bortezomib. ACS Chem. Neurosci. 11, 1337\u20131346 (2020).","journal-title":"ACS Chem. Neurosci."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03535-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03535-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03535-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:34:37Z","timestamp":1669919677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03535-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,5]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["3535"],"URL":"https:\/\/doi.org\/10.1038\/s41419-021-03535-9","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,5]]},"assertion":[{"value":"5 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study did not require ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"251"}}